Head & Neck Cancer Clinical Trials

10 recruiting

Head & Neck Cancer Trials at a Glance

9 actively recruiting trials for head & neck cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Göttingen, Kazan', and Krasnoyarsk. Lead sponsors running head & neck cancer studies include European Institute of Oncology, Kidney Cancer Research Bureau, and Centre Henri Becquerel.

Browse head & neck cancer trials by phase

Treatments under study

About Head & Neck Cancer Clinical Trials

Looking for clinical trials for Head & Neck Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head & Neck Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head & Neck Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting

Role of the Immune System in Preventing Laryngeal Cancer

Head & Neck Cancer
European Institute of Oncology3 enrolled1 locationNCT07508319
Recruiting

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
University of Rome Tor Vergata25 enrolled1 locationNCT07448727
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Not Applicable

Improving Dental Care for Patients With Head and Neck Tumors

Head & Neck CancerOral Health CareOral Health Behavior Change+2 more
University Medical Center Goettingen132 enrolled1 locationNCT07328347
Recruiting
Phase 2

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Head & Neck Cancer
Tang-Du Hospital10 enrolled1 locationNCT07353723
Recruiting
Phase 3

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute335 enrolled1 locationNCT07333274
Recruiting
Phase 2Phase 3

Contrast-enhanced Ultrasound for Sentinel Node Detection

Breast CancerMelanomaHead & Neck Cancer
The Netherlands Cancer Institute91 enrolled1 locationNCT07310758
Recruiting
Not Applicable

Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer

Head & Neck Cancer
Centre Henri Becquerel10 enrolled1 locationNCT07285564